Recombinant human antithrombin (rhAT)

BIOLOGICAL2 trials

Sponsors

rEVO Biologics

Conditions

Antithrombin Deficiency, CongenitalAntithrombin III Deficiency

Phase 3

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

CompletedNCT00056550

rEVO BiologicsAntithrombin Deficiency, Congenital

Start: 2002-12-31End: 2004-02-29Updated: 2012-10-16

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

CompletedNCT00110513

rEVO BiologicsAntithrombin III Deficiency

Start: 2005-04-30End: 2008-07-31Updated: 2012-08-17